Bacillus coagulans: a spore passing through, not a resident

A living bacterium that sits in a chocolate bar, goes through a baking oven, gets swallowed with hot coffee and still works at the far end sounds like a marketing claim. Here it is mostly chemistry. This organism makes an endospore — a dormant, armoured copy of itself — and the lactic acid bacteria you know from yoghurt almost never do. That single trait is why it turns up in chewing gum, cereal bars, lozenges and toothpaste while a Lactobacillus needs a cold shelf.

It is also why the canning industry has a file on it. The same armour that carries a probiotic through your stomach carries a spoilage organism through a pasteuriser. The same trait, opposite consequences. An honest entry has to print both.

What it is, in a sentence

Bacillus coagulans, validly also Heyndrickxia coagulans, is a Gram-positive, spore-forming, facultatively anaerobic bacterium that ferments sugars into lactic acid — built like a Bacillus, behaving like a lactic acid bacterium.

Where it lives in the body — and where it doesn't

Start with where it lives outside you: soil, plants, fermented foods, spoiled milk. That is its home. Your body is a corridor.

The best evidence for what happens inside comes from Duncan and colleagues at the University of Milan, who characterised strain LMG S-24828, originally isolated from healthy human faeces. The spores survived simulated gastric and intestinal transit, adhered to intestinal epithelial cells, and showed significant germination in the human gut ³. So it is not inert cargo. It wakes up, it metabolises, and then it leaves.

What it does not do is colonise. There is no established resident population of this species in a human gut or a human mouth the way there is for Bacteroides or Streptococcus mitis. Stop taking it and it goes. Every benefit below is therefore a benefit of ongoing intake, not of a changed ecosystem.

Say the caveat out loud: germination in the living gut was shown for one strain, in one study ³. That is a real finding. It is not a licence to say it about every product on the shelf.

What it does for us

In the mouth. The synthesis to point at is a systematic review and meta-analysis by Cirio and colleagues at the University of Milan, published in Frontiers in Oral Health in January 2026 ¹. Eight studies met inclusion — seven randomised trials and one non-randomised study — with 30 to 183 participants each, aged 5 to 73 ¹. Delivered as chewable tablets, mouthwash or food, the bacterium was associated with lower salivary Streptococcus mutans, the organism most associated with dental caries — though read the adult studies carefully: in the two that baked it into cake, the probiotic group did not fall, the placebo group rose ¹. Two studies, one in gingivitis and one in chronic periodontitis, reported improvement in gingival index, bleeding on probing and clinical attachment level; in the periodontitis trial the only measure that beat the control arm was gingival bleeding index ¹. No significant adverse events were reported ¹.

Now the caveat, and it is not a small one. Only three of the eight studies could be pooled at all, and the pooled effect was −0.74, 95 % confidence interval −1.38 to −0.10, with heterogeneity I² = 98.3 % ¹. That is nearly the ceiling. It means those three studies disagreed with each other so violently that the pooled figure summarises a disagreement rather than measuring an effect. One more thing worth knowing before you quote it: the paper's abstract prints a different number — −0.99 from four studies — than its own results section and forest plot, and the results section is the one to cite ¹. The direction is consistent — S. mutans goes down. The size of the drop is not established, and the authors' own conclusion is that current evidence is insufficient to support clinical efficacy in oral health ¹.

In the gut. Randomised, placebo-controlled trials, all in irritable bowel syndrome. Madempudi and colleagues randomised 136 adults to strain Unique IS2 at 2 billion CFU daily or placebo for 8 weeks, and reported significant improvement in abdominal pain and bowel movement endpoints ⁴. Majeed and colleagues gave 36 patients with diarrhoea-predominant IBS strain MTCC 5856 at 2 × 10⁹ CFU per day alongside standard care for 90 days, with reduced bloating, pain and stool frequency ⁵. Shaikh and Kumar followed 100 participants on strain BCP92 for 12 weeks and reported improved IBS severity and stool consistency ⁹.

Here is the part the supplement copy leaves out. Both trials that measured inflammation found none of it moving. Madempudi measured IL-6, IL-12, TNF-α, IFN-γ and IL-10 and found no significant change against placebo at eight weeks ⁴. Shaikh and Kumar measured IL-6 and found no significant change ⁹. The benefit in these trials was symptomatic. If someone tells you this organism works by calming inflammation, ask them which study measured the cytokines — because the two that did came back flat.

One more thing belongs in the sentence: several of these trials were designed or funded by the companies that manufacture the strain. That is the norm in probiotic research rather than a scandal, but it is a reason to want independent replication before treating any of it as settled.

What it does against us

It spoils food. Misiou and colleagues built a validated growth model for B. coagulans DSM 1 and put numbers on the risk: growth begins around 23.77 °C, peaks at 52.89 °C, ceases near 59.37 °C, and continues down to pH 4.70 ⁶. Read that as a description of a warm, acidic, shelf-stable ready meal. The spores survive the heat step, the product sits warm in transit, the organism germinates and sours it — and because it produces acid without much gas, the packaging does not swell. Nothing looks wrong until you taste it.

It is a live organism, and live organisms occasionally get in where they shouldn't. There is no outbreak here and no reason for alarm, but the mechanism is real: a damaged intestinal lining, a central venous catheter or a suppressed immune system can let a swallowed bacterium into the bloodstream. Qi and colleagues used whole-genome sequencing to match blood-culture isolates in an 85-year-old man after pancreatic surgery to the probiotic capsules he had been given ⁸. State plainly what that case is and is not: it involved Bacillus licheniformis and Lactiplantibacillus plantarum, not this species. The principle generalises; the case does not.

The safety literature is thinner than it looks. The AHRQ review by Hempel and colleagues screened 11 977 publications and included 622 studies on probiotic safety ⁷. Across randomised trials there was no statistically significant increase in adverse events: relative risk 1.00, 95 % confidence interval 0.93 to 1.07 for the overall number of adverse events, and 1.06, 0.97 to 1.16 for other events including serious ones ⁷. But the authors' own conclusion was that adverse events were poorly documented and rare harms remain hard to detect. That is the correct line to carry: not evidence of danger, and not proof of safety either.

And the details are strain-level, not species-level. Duncan's team tested their strain specifically for D-lactate production, bile-salt deconjugation, haemolysis and transmissible antibiotic resistance genes, and found none ³. Useful — and it tells you those are properties worth checking in each strain, not guarantees you inherit from the species name.

The name changed

The species was described as Bacillus coagulans. Genome-based work moved it first to Weizmannia (Gupta and colleagues, 2020), and then a reclassification published in the International Journal of Systematic and Evolutionary Microbiology in 2023 transferred it to Heyndrickxia, giving the combination Heyndrickxia coagulans ².

Here is the part usually reported backwards. The DSMZ's List of Prokaryotic names with Standing in Nomenclature lists all three as homotypic synonyms of one organism — and it keeps Bacillus coagulans as the correct name, explicitly recommended for medical use, holding the Heyndrickxia combination in taxonomic suspension until no later than 2028. NCBI Taxonomy, which is not a nomenclatural authority, has already filed the organism (taxid 1398) under Heyndrickxia coagulans. So the new name is valid, but it is not yet the one you are supposed to use in a clinical sentence.

Either way, neither name is a different bug.

What is still unknown

Whether lowering salivary S. mutans — the cavity bacterium in saliva — actually produces fewer cavities: no trial has counted them. How long any effect lasts after you stop taking it. And whether results from one strain transfer to the next one — on the current evidence, assume they do not.